Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
6.37
-0.19 (-2.90%)
At close: Aug 10, 2026, 4:00 PM EDT
6.37
0.00 (0.00%)
After-hours: Aug 10, 2026, 4:58 PM EDT

Taysha Gene Therapies Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
2,0381,568355331141448
Market Cap Growth
179.24%342.19%7.14%134.50%-68.52%-55.28%
Enterprise Value
1,8291,316276.37245.99111.65362.21
Last Close Price
6.375.501.731.772.2611.65
PS Ratio
272.72160.4242.5521.4256.40-
PB Ratio
8.636.354.964.42148.704.70
P/TBV Ratio
10.337.126.052.74104.674.60
EV/Sales Ratio
244.88134.6433.1715.9244.62-
Debt / Equity Ratio
0.310.280.860.7961.550.66
Net Debt / Equity Ratio
-0.99-1.02-1.09-1.13-31.06-0.90
Net Debt / EBITDA Ratio
1.602.300.871.200.180.50
Net Debt / FCF Ratio
1.872.690.961.110.270.65
Asset Turnover
0.020.040.050.100.010
Quick Ratio
13.7812.065.323.931.402.88
Current Ratio
14.0412.235.424.081.543.08
Return on Equity (ROE)
-56.61%-68.45%-121.94%-294.04%-344.67%-100.68%
Return on Assets (ROA)
-41.19%-43.88%-54.91%-48.45%-95.49%-73.29%
Return on Invested Capital (ROIC)
-720.96%-598.79%-445.09%-274.80%-385.80%-626.01%
Return on Capital Employed (ROCE)
-44.41%-49.01%-67.72%-72.63%-143.95%-83.71%
Buyback Yield / Dilution
-32.50%-27.82%-115.41%-164.20%-16.74%-113.13%
Total Shareholder Return
-32.50%-27.82%-115.41%-164.20%-16.74%-113.13%
SEC Filings: 10-K · 10-Q